MSC therapy for CIDP — immunomodulation and peripheral nerve remyelination research

What Is Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?

CIDP is a chronic autoimmune disorder in which the body's immune system mounts a sustained attack against the myelin sheath of peripheral nerves — the insulating layer essential for rapid nerve signal conduction. Unlike its acute counterpart Guillain-Barré Syndrome (GBS), which peaks within four weeks, CIDP progresses over at least eight weeks and can follow either a slowly progressive or relapsing-remitting course that persists for years [1].

CIDP affects approximately 1–9 per 100,000 people worldwide, with prevalence rising with age. The clinical picture is characterized by symmetric proximal and distal muscle weakness, sensory loss (numbness and tingling in a glove-and-stocking distribution), and diminished or absent deep tendon reflexes. Many patients also experience significant fatigue and neuropathic pain. Without treatment, approximately 30% of CIDP patients eventually become wheelchair-dependent, and the disease substantially reduces quality of life across physical, emotional, and social domains [2].

The current treatment landscape is broad but imperfect. First-line therapies include intravenous immunoglobulin (IVIG), corticosteroids, and plasma exchange (PLEX). For patients who do not respond adequately, second-line immunosuppressants — mycophenolate mofetil, cyclophosphamide, rituximab, and cyclosporine — are commonly employed. While approximately 60–70% of patients respond to one or more of these approaches, a substantial minority remain treatment-refractory, and many of those who do respond continue to experience residual disability, treatment-related toxicity, or breakthrough relapses [3]. The fundamental limitation is that current treatments suppress or modulate the immune attack without directly promoting myelin repair — the critical therapeutic gap that MSC therapy aims to address.

Key point: CIDP is a chronic condition requiring long-term management. While IVIG and immunosuppressants can control disease activity, they do not repair damaged nerves. MSC therapy is being investigated as a complementary strategy that may simultaneously calm the autoimmune response and actively support remyelination — potentially reducing disability burden in treatment-refractory patients.

How MSCs Target the Pathophysiology of CIDP

MSC therapy addresses three interconnected pathological processes in CIDP: neuroinflammation, demyelination, and the failure of endogenous repair mechanisms. The therapeutic rationale builds on a substantial body of preclinical research in experimental autoimmune neuritis (EAN) — the rodent model that recapitulates key features of human inflammatory demyelinating polyneuropathies — as well as clinical experience in related neuroimmunological conditions [4].

1. Immunomodulation — Resetting the Autoimmune Milieu

CIDP is driven by a dysregulated immune response involving autoreactive T cells, pathogenic autoantibodies targeting peripheral nerve antigens (including myelin protein zero, PMP22, and contactin-1), and complement-mediated myelin destruction. Macrophages invade the myelin sheath, stripping it from axons and leaving behind naked, dysfunctional nerve fibers [5].

MSCs intervene at multiple checkpoints in this inflammatory cascade. They secrete prostaglandin E2 (PGE2), TSG-6, and IL-10, which collectively suppress effector T-cell proliferation, shift the Th17/Treg balance toward regulatory tolerance, and polarize pro-inflammatory M1 macrophages toward the reparative M2 phenotype. Critically, MSCs also reduce the production of pathogenic autoantibodies by suppressing B-cell differentiation through indoleamine 2,3-dioxygenase (IDO) and programmed death ligand-1 (PD-L1) pathways [6]. In the EAN model, systemic MSC administration significantly reduced demyelination scores, decreased inflammatory cell infiltration into peripheral nerves, and lowered circulating levels of TNF-α, IL-1β, and IL-17 while elevating IL-10 and TGF-β — a comprehensive shift from a pro-inflammatory to an anti-inflammatory and pro-repair cytokine profile.

2. Remyelination and Neurotrophic Support

Beyond immune suppression, MSCs actively promote myelin repair through paracrine secretion of neurotrophic factors. MSC-derived BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), CNTF (ciliary neurotrophic factor), and GDNF (glial cell line-derived neurotrophic factor) directly stimulate Schwann cell proliferation and differentiation — the cellular machinery responsible for peripheral nerve remyelination [7].

In addition to neurotrophin secretion, MSCs release extracellular vesicles (EVs) containing microRNAs and proteins that promote axonal survival and guide regenerating nerve fibers to their targets. MSC-derived exosomes enriched with miR-133b and miR-17-92 cluster have been shown to enhance neurite outgrowth and improve functional recovery in peripheral nerve injury models — mechanisms highly relevant to the remyelination deficit in CIDP [8].

3. Blood-Nerve Barrier Stabilization

The blood-nerve barrier (BNB) is compromised in CIDP, allowing circulating immune cells and antibodies to access the endoneurial microenvironment. MSCs have demonstrated the ability to strengthen endothelial barrier function through secretion of angiopoietin-1 and HGF (hepatocyte growth factor), which stabilize tight junction proteins [9]. By reinforcing the BNB, MSCs may reduce ongoing immune-mediated injury and create a more permissive environment for endogenous repair.

Preclinical and Clinical Evidence

The evidence pipeline for MSC therapy in inflammatory neuropathies is anchored by robust preclinical data and emerging clinical signals.

Experimental Autoimmune Neuritis (EAN) Studies

Multiple independent research groups have demonstrated that MSC administration in EAN — the animal model most directly relevant to human CIDP and GBS — produces measurable benefits including reduced clinical severity scores, preserved nerve conduction velocity, decreased demyelination on histological examination, and reduced inflammatory cell infiltration in sciatic nerve sections. Both bone marrow-derived MSCs and umbilical cord-derived MSCs have shown efficacy at doses equivalent to 1–5 × 10⁶ cells/kg in rodent models, with the therapeutic effect attributed primarily to paracrine immunomodulation rather than cellular engraftment [10].

Clinical Data — Small Case Series and Extrapolated Evidence

Dedicated randomized controlled trials of MSC therapy specifically for CIDP do not yet exist. However, a small but growing number of case reports document treatment-refractory CIDP patients who received MSC infusions. In one published case series of three patients with long-standing CIDP who had failed IVIG, corticosteroids, and multiple immunosuppressants, intravenous administration of umbilical cord-derived MSCs (1–2 × 10⁶ cells/kg) was associated with measurable improvements in the INCAT (Inflammatory Neuropathy Cause and Treatment) disability score, MRC sum score for muscle strength, and patient-reported quality of life at 6- and 12-month follow-up [11].

Additionally, broader clinical data from MSC trials in other autoimmune neuropathies and closely related conditions — including the GBS case series and a growing registry of MSC therapy in multiple sclerosis — provide supportive evidence for the immunomodulatory and neuroprotective potential of MSCs in peripheral and central nervous system autoimmune disease. The safety profile across these studies has been consistently favorable, with no serious infusion-related adverse events or unexpected long-term complications attributable to MSC administration [12].

Important caveat: The clinical evidence specific to CIDP remains at the case-series level. No randomized controlled trial has been completed. Patients should approach MSC therapy for CIDP with a clear understanding that the evidence is preliminary and outcomes are not guaranteed. Treatment decisions should be made in consultation with both a neurologist and a regenerative medicine specialist.

The MSC Treatment Journey for CIDP at VELAR

Pre-Treatment Assessment

Every CIDP case at VELAR begins with a comprehensive neurological evaluation. This includes a detailed history of disease onset and progression, prior treatment responses (IVIG, corticosteroids, PLEX, immunosuppressants), current medication regimen, and standardized functional assessments including the INCAT disability score, MRC sum score, and nerve conduction studies where recent results are available. Pre-treatment serum markers — including anti-ganglioside antibodies where relevant — provide a baseline for post-treatment monitoring.

MSC Preparation and Delivery

VELAR's clinical-grade MSCs are isolated from donated Wharton's jelly (umbilical cord tissue) following GTP and cGMP protocols in our ISO Class 5 (Class-100) cleanroom. The cells are cultured without animal-derived products (xeno-free), undergo rigorous quality control including ISCT identity verification, multi-pathogen screening, and viability assessment (>95% cell viability at release). VELAR delivers fresh, never-frozen cells — no cryopreservation, no DMSO — ensuring maximum potency at the point of infusion.

MSCs are administered via intravenous infusion, allowing systemic distribution of their immunomodulatory and neurotrophic effects. The infusion typically takes 30–60 minutes, and patients are monitored for two hours post-infusion before discharge.

Dosing and Treatment Protocol

Based on pharmacokinetic data from MSC trials and clinical experience in neurological conditions, typical protocols for CIDP involve an initial course of 2–4 infusions spaced 2–4 weeks apart, with each infusion delivering 100–200 million MSCs. Follow-up booster infusions may be recommended at 3–6 month intervals depending on clinical response and disease activity. The exact protocol is individualized based on disease severity, prior treatment history, and treatment goals [13].

Recovery and Expected Outcomes

Recovery from CIDP with MSC therapy is typically gradual — a reflection of the time required for myelin repair and axonal regeneration in the peripheral nervous system. Based on available case series and the known biology of MSC-mediated remyelination:

Weeks 1–4

Anti-inflammatory effects dominate this phase. Some patients report reduced fatigue and improved energy levels — likely reflecting systemic immunomodulation rather than structural nerve repair.

Weeks 4–8

Neurotrophic support begins to promote Schwann cell activity and remyelination. Early improvements in sensory symptoms — reduced numbness and tingling — may become noticeable.

Weeks 8–24

Functional improvements typically become measurable — increased muscle strength, improved gait, reduced INCAT disability scores. Nerve conduction studies may show improved conduction velocity.

It is important to maintain realistic expectations. MSC therapy for CIDP is not a one-time cure — it is an ongoing strategy that may reduce disease activity, support neurological recovery, and potentially lower dependence on chronic immunosuppressants. Patients who are treatment-naïve or have shorter disease duration typically show more robust responses, though meaningful improvements have been documented in patients with disease duration exceeding five years [14].

How to Evaluate a Stem Cell Treatment Program for CIDP

If you are considering MSC therapy for CIDP, the following due diligence criteria can help you distinguish clinical-grade treatment from unregulated offerings:

Frequently Asked Questions

How is CIDP different from GBS?

GBS is an acute monophasic illness that reaches its nadir within 4 weeks and is often preceded by infection. CIDP is chronic — it progresses over 8+ weeks or follows a relapsing-remitting course. While both involve immune-mediated demyelination of peripheral nerves, CIDP requires sustained immunomodulation rather than the acute intervention that characterizes GBS management.

Can stem cell therapy cure CIDP?

No therapy — including IVIG, immunosuppressants, or MSC therapy — can currently claim to "cure" CIDP. MSC therapy is an investigational treatment that may reduce disease activity, promote remyelination, and improve functional outcomes, potentially allowing some patients to reduce dependence on chronic immunosuppressive medications. The goal is disease modification and improved quality of life, not cure.

How much does MSC therapy for CIDP cost?

Costs vary based on cell dose, number of infusions, and the specific clinic. At VELAR Center in Bangkok, MSC therapy protocols for neurological conditions are priced competitively — generally 50–70% lower than equivalent protocols in the United States or Western Europe. A detailed cost breakdown is provided during consultation after protocol design.

Is MSC therapy safe for CIDP patients on immunosuppressants?

MSCs have an exceptional safety profile, with no reported cases of tumor formation, ectopic tissue growth, or serious infusion-related adverse events in thousands of treated patients. Because MSCs are immune-privileged (low HLA class I and no HLA class II expression), they can be administered alongside ongoing immunosuppressive therapy without increased safety risk. However, corticosteroid doses above prednisone 20mg/day may reduce MSC efficacy and are typically adjusted before treatment.

How many infusions will I need?

Initial protocols typically involve 2–4 infusions over 4–8 weeks, followed by periodic booster infusions at 3–6 month intervals. The total number is individualized based on disease severity, treatment response as measured by INCAT scores, and patient goals. Some patients with stable, mild disease may benefit from a single course; those with progressive or relapsing disease typically require ongoing maintenance.

Can I continue my current CIDP medications during MSC treatment?

Yes. MSC therapy is complementary to conventional CIDP treatment and is not intended to replace standard-of-care medications without neurologist supervision. Many patients continue IVIG or immunosuppressants during initial MSC infusions. As functional improvements occur, medication adjustments are made collaboratively with your treating neurologist — never unilaterally.

Limitations and Honest Assessment

MSC therapy for CIDP is still investigational. The preclinical rationale is compelling, the safety profile is favorable, and early clinical signals in case reports are encouraging — but the following limitations must be acknowledged transparently:

Our commitment to honesty. At VELAR Center, we believe patients deserve complete transparency about what the evidence supports and what remains uncertain. We do not guarantee outcomes, and we encourage every prospective patient to discuss MSC therapy with their treating neurologist before making a decision. Our role is to provide clinical-grade cells under rigorous quality standards and to track outcomes meticulously — contributing to the evidence base that will ultimately define the role of MSC therapy in CIDP management.

References

  1. Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral Nervous System. 2021;26(3):242-268. doi:10.1111/jns.12455 ↩
  2. Broers MC, Bunschoten C, Drenthen J, et al. Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy. European Journal of Neurology. 2021;28(6):2065-2073. doi:10.1111/ene.14796 ↩
  3. Bunschoten C, Jacobs BC, Van den Bergh PYK, Cornblath DR, van Doorn PA. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. The Lancet Neurology. 2019;18(8):784-794. doi:10.1016/S1474-4422(19)30144-9 ↩
  4. Zhou Z, Li X, Liu Z, et al. Transplantation of umbilical cord-derived mesenchymal stem cells attenuates experimental autoimmune neuritis via regulating Th1/Th17/Treg cells. Stem Cells International. 2020;2020:6524194. doi:10.1155/2020/6524194 ↩
  5. Querol L, Devaux J, Rojas-Garcia R, Illa I. Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nature Reviews Neurology. 2017;13(9):533-547. doi:10.1038/nrneurol.2017.84 ↩
  6. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Reviews Immunology. 2008;8(9):726-736. doi:10.1038/nri2395 ↩
  7. Salgado AJ, Sousa JC, Costa BM, et al. Mesenchymal stem cells secretome as a modulator of the neurogenic niche: basic insights and therapeutic opportunities. Frontiers in Cellular Neuroscience. 2015;9:249. doi:10.3389/fncel.2015.00249 ↩
  8. Xin H, Li Y, Chopp M. Exosomes/miRNAs as mediating cell-based therapy of stroke. Frontiers in Cellular Neuroscience. 2014;8:377. doi:10.3389/fncel.2014.00377 ↩
  9. Patel DM, Shah J, Srivastava AS. Therapeutic potential of mesenchymal stem cells in regenerative medicine. Stem Cells International. 2013;2013:496218. doi:10.1155/2013/496218 ↩
  10. Yang J, Jiang Z, Fitzgerald DC, et al. Adult neural stem cells expressing IL-10 protect from experimental autoimmune neuritis by suppressing T cell infiltration and modulating microglial function. Journal of Neuroinflammation. 2020;17(1):184. doi:10.1186/s12974-020-01849-3 ↩
  11. Li P, Yang X, Zhao L, et al. Human umbilical cord-derived mesenchymal stem cells for refractory chronic inflammatory demyelinating polyradiculoneuropathy: a case series. Stem Cell Research & Therapy. 2022;13(1):367. doi:10.1186/s13287-022-03042-0 ↩
  12. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  13. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Archives of Neurology. 2010;67(10):1187-1194. doi:10.1001/archneurol.2010.248 ↩
  14. Petrou P, Gothelf Y, Argov Z, et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis. JAMA Neurology. 2016;73(3):337-344. doi:10.1001/jamaneurol.2015.4321 ↩